PBPIA
MPLT

Pivotal bioVenture Partners Investment Advisor’s MapLight Therapeutics MPLT Stock Holding History

Pivotal bioVenture Partners Investment Advisor’s Portfolio MPLT Stock Details MPLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$12.4M Hold
611,447
– – 4.44% 7
2025
Q4 		$10.7M Buy
+611,447
New +$10.2M 4.15% 8

Other funds holding MPLT

NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Pivotal bioVenture Partners Investment Advisor's MPLT Position: Q1 2026 in Review

Pivotal bioVenture Partners Investment Advisor held its MapLight Therapeutics (MPLT) position steady in Q1 2026 at 611,447 shares worth $12.4M. The position accounts for 4.44% of the portfolio, ranked #7.

Pivotal bioVenture Partners Investment Advisor first reported a position in MPLT in Q4 2025 and has held it in 2 quarters since. 81 funds tracked by Wall St. Rank hold MPLT as of Q1 2026.

  • Pivotal bioVenture Partners Investment Advisor held 611,447 shares of MapLight Therapeutics worth $12.4M as of Q1 2026.
  • Pivotal bioVenture Partners Investment Advisor left its MapLight Therapeutics share count unchanged in Q1 2026.
  • MapLight Therapeutics made up 4.44% of Pivotal bioVenture Partners Investment Advisor's portfolio in Q1 2026, its #7 holding.
  • Pivotal bioVenture Partners Investment Advisor first reported a position in MapLight Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 81 funds tracked by Wall St. Rank held MapLight Therapeutics as of Q1 2026.

Based on Pivotal bioVenture Partners Investment Advisor's 13F filing for Q1 2026, filed 14 May 2026.